Myocardial Assistance by Grafting a New Bioartificial Upgraded Myocardium (MAGNUM Clinical Trial): One Year Follow-Up
Open Access
- 1 October 2007
- journal article
- Published by SAGE Publications in Cell Transplantation
- Vol. 16 (9) , 927-934
Abstract
Cell transplantation for the regeneration of ischemic myocardium is limited by poor graft viability and low cell retention. In ischemic cardiomyopathy the extracellular matrix is deeply altered; therefore, it could be important to associate a procedure aiming at regenerating myocardial cells and restoring the extracellular matrix function. We evaluated intrainfarct cell therapy associated with a cell-seeded collagen scaffold grafted onto infarcted ventricles. In 15 patients (aged 54.2 ± 3.8 years) presenting LV postischemic myocardial scars and with indication for a single OP-CABG, autologous mononuclear bone marrow cells (BMC) were implanted during surgery in the scar. A 3D collagen type I matrix seeded with the same number of BMC was added on top of the scarred area. There was no mortality and no related adverse events (follow-up 15 ± 4.2 months). NYHA FC improved from 2.3 ± 0.5 to 1.4 ± 0.3 (p = 0.005). LV end-diastolic volume evolved from 142 ± 24 to 117 ± 21 ml (p = 0.03), and LV filling deceleration time improved from 162 ± 7 to 196 ± 8 ms (p = 0.01). Scar area thickness progressed from 6 ± 1.4 to 9 ± 1.5 mm (p = 0.005). EF improved from 25 ± 7% to 33 ± 5% (p = 0.04). Simultaneous intramyocardial injection of mononuclear bone marrow cells and fixation of a BMC-seeded matrix onto the epicardium is feasible and safe. The cell-seeded collagen matrix seems to increase the thickness of the infarct scar with viable tissues and helps to normalize cardiac wall stress in injured regions, thus limiting ventricular remodeling and improving diastolic function. Patients' improvements cannot be conclusively related to the cells and matrix due to the association of CABG. Cardiac tissue engineering seems to extend the indications and benefits of stem cell therapy in cardiology, becoming a promising way for the creation of a “bioartificial myocardium.” Efficacy and safety of this approach should be evaluated in a large randomized controlled trial.Keywords
This publication has 32 references indexed in Scilit:
- Massive mechanical loss of microspheres with direct intramyocardial injection in the beating heart: Implications for cellular cardiomyoplastyThe Journal of Thoracic and Cardiovascular Surgery, 2006
- Cell replacement therapy: The functional importance of myocardial architecture and intercellular gap-junction distributionThe Journal of Thoracic and Cardiovascular Surgery, 2006
- History of Tissue Engineering and A Glimpse Into Its FutureTissue Engineering, 2006
- Electrical Coupling of Cardiac Myocyte Cell Sheets to the HeartCirculation Research, 2006
- Cell transplantation preserves matrix homeostasis: A novel paracrine mechanismThe Journal of Thoracic and Cardiovascular Surgery, 2005
- Cardiac extracellular matrix: a dynamic entityAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005
- Myocardial Restoration With Embryonic Stem Cell Bioartificial Tissue TransplantationThe Journal of Heart and Lung Transplantation, 2005
- Injectable Self-Assembling Peptide Nanofibers Create Intramyocardial Microenvironments for Endothelial CellsCirculation, 2005
- Cellular cardiomyoplasty: clinical applicationThe Annals of Thoracic Surgery, 2004
- Tissue EngineeringScience, 1993